Drug Trial Radar · NCT01004861
Safety Study of PLX108-01 in Patients With Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jan 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
132
Actual
Start
Oct 1, 2009
Primary completion
Jan 31, 2018
Study completion Oct 25, 2018
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- Plexxikon
- First posted
- Oct 30, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity. The primary objective of this study is to evaluate the safety and pharmacokinetics of orally administered PLX3397 in patients with advanced, incurable, solid tumors in which these target kinases are linked to disease pathophysiology. The secondary objective is to measure the pharmacodynamic activity of PLX3397 via blood, plasma and urine biomarkers of Fms activity.
Conditions
- Solid Tumor
Interventions
PLX3397Drug
Capsules administered once or twice daily, continuous dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Summary of Derived Best Tumor Response Per the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 - Dose Escalation (Efficacy Evaluable Population)Time frame: Every 2 months beginning Cycle 3, Day 1 until disease progression (up to approximately 30 months postdose)
- Summary of Derived Best Tumor Response Per the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 - Dose Extension (Efficacy Evaluable Population)Time frame: Every 2 months beginning Cycle 3, Day 1 until disease progression (up to approximately 30 months postdose)
- Duration of Response (Efficacy Evaluable Population) - Dose ExtensionTime frame: From initial response until disease progression or death, up to approximately 30 months postdose
- Progression-free Survival (Efficacy Evaluable Population) - Dose ExtensionTime frame: From Cycle 1 Day 1 to disease progression or death
- Best Overall Tumor Response (PVNS Cohort) Per the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 - Dose ExtensionTime frame: Every 2 months beginning Cycle 3, Day 1 until disease progression
- Summary Statistics for Selected PLX3397 Pharmacokinetics Parameter Cmax, Study Day Cycle 1 Day 15, Stratified by Cohort - Dose EscalationTime frame: Cycle 1, Day 15
- Summary Statistics for Selected PLX3397 Pharmacokinetics Parameter Tmax, Study Day Cycle 1 Day 15, Stratified by Cohort - Dose EscalationTime frame: Cycle 1, Day 15
- Summary Statistics for Selected PLX3397 Pharmacokinetics Parameter Area Under the Curve (AUC0-24), Study Day Cycle 1 Day 15, Stratified by Cohort - Dose EscalationTime frame: Cycle 1, Day 15 (QD dosing: predose [morning] and 0.5, 1, 2, 4, and 8 hours postdose; BID dosing: predose [morning] and 1, 2, 4, and 7 hours postdose)
- Numeric Rating Scale (NRS) for PVNS Symptoms Sum of Scores Through Cycle 2 (Efficacy Evaluable Population) - Dose ExtensionTime frame: Baseline, Cycle 1 Day 15, Cycle 2, Cycle 3, Cycle 12, Cycle 24, Cycle 36, and Cycle 46 (each cycle was 28 days)
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
HonorHealth
Scottsdale, Arizona
UCLA
Los Angeles, California
Rocky Mountain Cancer Centers
Denver, Colorado
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Memorial Sloan-Kettering Cancer Center (MSKCC)
New York, New York
Pennsylvania Oncology Hematology Associates
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Vanderbilt-Ingram Medical Center
Nashville, Tennessee
Texas Oncology, PA (North)
Dallas, Texas
Virginia Oncology Associates
Norfolk, Virginia
Evergreen Hematology & Oncology
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.